Physiomics biological systems computer modelling techniques, known as in silico simulation, will be used to support Lilly’s cancer drug discovery research. The company will work alongside Lilly’s global PK/PD/TS (pharmacokinetics, pharmacodynamics and trial simulation) department and oncology discovery group.
The research programme will initially focus on drugs aimed at restoring the cell cycle – the natural process of controlling cell proliferation – which is frequently disrupted in cancers.
Dr Christophe Chassagnole, chief operating officer of Physiomics, said: ‘This is a very positive step forward for Physiomics as a further major pharmaceutical company joins our growing list of partners at a time when interest in application of systems biology to pharmaceutical R&D is increasing very rapidly.’
Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. The company has created detailed mathematical models incorporating most important molecular events taking place during the human cell cycle and apoptosis processes, including multi-cellular environment software which enables the simulation of a population of ‘virtual cells’.